123 related articles for article (PubMed ID: 38704960)
1. Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S
Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960
[TBL] [Abstract][Full Text] [Related]
2. Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity.
Loizidou EZ; Zeinalipour-Yazdi CD
Chem Biol Drug Des; 2014 Jul; 84(1):99-107. PubMed ID: 24521156
[TBL] [Abstract][Full Text] [Related]
3. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK
Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
5. Proteasome activity imaging and profiling characterizes bacterial effector syringolin A.
Kolodziejek I; Misas-Villamil JC; Kaschani F; Clerc J; Gu C; Krahn D; Niessen S; Verdoes M; Willems LI; Overkleeft HS; Kaiser M; van der Hoorn RA
Plant Physiol; 2011 Jan; 155(1):477-89. PubMed ID: 21045122
[TBL] [Abstract][Full Text] [Related]
6. Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM
J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994
[TBL] [Abstract][Full Text] [Related]
7. Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I.
Amatuni A; Shuster A; Adibekian A; Renata H
Cell Chem Biol; 2020 Oct; 27(10):1318-1326.e18. PubMed ID: 32763140
[TBL] [Abstract][Full Text] [Related]
8. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
Klein M; Busch M; Friese-Hamim M; Crosignani S; Fuchss T; Musil D; Rohdich F; Sanderson MP; Seenisamy J; Walter-Bausch G; Zanelli U; Hewitt P; Esdar C; Schadt O
J Med Chem; 2021 Jul; 64(14):10230-10245. PubMed ID: 34228444
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and highly specific β
Zhou T; Cai Y; Liang L; Yang L; Xu F; Niu Y; Wang C; Zhang JL; Xu P
Bioorg Med Chem Lett; 2016 Dec; 26(23):5780-5784. PubMed ID: 27816516
[TBL] [Abstract][Full Text] [Related]
11. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
[TBL] [Abstract][Full Text] [Related]
12. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Totaro KA; Barthelme D; Simpson PT; Jiang X; Lin G; Nathan CF; Sauer RT; Sello JK
ACS Infect Dis; 2017 Feb; 3(2):176-181. PubMed ID: 28183185
[TBL] [Abstract][Full Text] [Related]
14. A panel of subunit-selective activity-based proteasome probes.
Verdoes M; Willems LI; van der Linden WA; Duivenvoorden BA; van der Marel GA; Florea BI; Kisselev AF; Overkleeft HS
Org Biomol Chem; 2010 Jun; 8(12):2719-27. PubMed ID: 20449511
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
16. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
19. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
